Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group
CONCLUSION: These GTH consensus recommendations provide guidance to physicians on the use of emicizumab in AHA and follow the results of clinical trials that have shown emicizumab is effective in preventing bleeding in AHA.PMID:38049124 | DOI:10.1055/a-2197-9738
Source: Hamostaseologie - Category: Hematology Authors: Christian Pfrepper Robert Klamroth Johannes Oldenburg Katharina Holstein Hermann Eichler Christina Hart Patrick Moehnle Kristina Schilling Karolin Trautmann-Grill Mohammed Alrifai Cihan Ay Wolfgang Miesbach Paul Knoebl Andreas Tiede Source Type: research
More News: Austria Health | Bleeding | Clinical Trials | Germany Health | Haemophilia | Hematology | Hemophilia | Study